Related Experiment Video
Updated: Nov 22, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
The miR-1906 mimic attenuates bone loss in osteoporosis by down-regulating the TLR4/MyD88/NF-κB pathway
1Department of Rehabilitation, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Abstract:
In this study, the ability of microRNA-1906 (miR-1906) to attenuate bone loss in osteoporosis was evaluated by measuring the effects of a miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of MC3T3-E1 cells. Bone marrow-derived macrophage (BMM) cells were isolated from female mice, and tartrate-resistant acid phosphatase signalling was performed in miR-1906 mimic-treated, receptor-activated nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced osteoclasts. In-vivo, osteoporosis was induced by ovariectomy (OVX). Rats were treated with 500 nmol/kg of the miR-1906 mimic via intrathecal administration for 10 consecutive days following surgery. The effect of the miR-1906 mimic on bone mineral density (BMD) in OVX rats was observed in the whole body, lumbar vertebrae and femur. Levels of biochemical parameters and cytokines in the serum of miR-1906 mimic-treated OVX rats were analysed. The mRNA expression of toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), p-38 and NF-κB in tibias of osteoporotic rats (induced by ovariectomy) was observed using quantitative reverse-transcription polymerase chain reaction. Treatment with the miR-1906 mimic reduced cellular toxicity and enhanced the cell viability of MC3T3-E1 cells. Furthermore, osteoclastogenesis in miR-1906 mimic-treated, RANKL-induced osteoclast cells was reduced, whereas the BMD in the miR-1906 mimic-treated group was higher than in the OVX group of rats. Treatment with the miR-1906 mimic also increased levels of biochemical parameters and cytokines in the serum of ovariectomised rats. Finally, mRNA expression levels of TLR4, MyD88, p-38 and NF-κB were lower in the tibias of miR-1906 mimic-treated rats than in those of OVX rats. In conclusion, the miR-1906 mimic reduces bone loss in rats with ovariectomy-induced osteoporosis by regulating the TLR4/MyD88/NF-κB pathway.
Insights
MicroRNA-1906 (miR-1906) mimic effectively reduces bone loss in osteoporosis by inhibiting osteoclastogenesis and regulating the TLR4/MyD88/NF-κB pathway. This study demonstrates miR-1906
Area of Science:
- Biomedical Science
- Molecular Biology
- Osteoporosis Research
Background:
- Osteoporosis is a significant skeletal disorder characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk.
- MicroRNAs (miRNAs) are emerging as key regulators of bone metabolism, offering potential therapeutic targets for osteoporosis.
- The specific role of microRNA-1906 (miR-1906) in modulating bone loss, particularly in the context of the Toll-like receptor 4 (TLR4) pathway, requires further elucidation.
Purpose of the Study:
- To evaluate the therapeutic potential of miR-1906 in attenuating bone loss in an osteoporosis model.
- To investigate the effects of miR-1906 on osteoclastogenesis and bone mineral density (BMD).
- To elucidate the molecular mechanisms underlying miR-1906's action, focusing on the TLR4/MyD88/NF-κB signaling pathway.
Main Methods:
- In vitro assessment of miR-1906 mimic and inhibitor on MC3T3-E1 cell viability and toxicity.
- Analysis of osteoclastogenesis in receptor-activated nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced osteoclasts treated with miR-1906 mimic.
- In vivo study using ovariectomy (OVX)-induced osteoporosis model in rats, treated intrathecally with miR-1906 mimic, followed by BMD, biochemical parameter, cytokine, and gene expression analysis.
Main Results:
- miR-1906 mimic treatment reduced cellular toxicity and enhanced MC3T3-E1 cell viability.
- Osteoclastogenesis was significantly inhibited in miR-1906 mimic-treated osteoclasts.
- OVX rats treated with miR-1906 mimic exhibited increased BMD and altered serum biochemical parameters and cytokines, with downregulated mRNA expression of TLR4, MyD88, p-38, and NF-κB in tibial tissues.
Conclusions:
- miR-1906 mimic demonstrates a protective effect against bone loss in an OVX-induced osteoporosis rat model.
- The therapeutic benefits of miR-1906 are mediated through the regulation of the TLR4/MyD88/NF-κB signaling pathway.
- miR-1906 represents a promising therapeutic candidate for the management of osteoporosis.
